Tag Archives: heart failure with preserved ejection fraction (HFpEF)

Professor Christopher Miller HFpEF on the rise: navigating the heterogeneity In an engaging opening talk, Professor Christopher Miller (University of Manchester) revealed heart failure with preserved ejection fraction (HFpEF) as the dominant form of heart failure (HF), rising by 10% every decade. Over 70% of patients with HF have HFpEF, most of whom are over 65 years of age experiencing complex comorbidities. The diagnostic challenges in heterogeneous groups were discussed against the background of the diagnostic criteria provided by European Society of Cardiology (ESC)1 as some patients with clinical signs of HFpEF show normal

Introduction In recent years heart failure with preserved ejection fraction (HFpEF) has become a research priority, since despite having a preserved ejection fraction (EF), it is still associated with mortality and survival rates similar to heart failure with a reduced ejection fraction (HFrEF).1 Historically, the interest in HFpEF stems from the collaboration of two areas of research. Studies found that diastolic left ventricular (LV) dysfunction contributed to myocardial hypertrophy.2,3 Shortly after, HFpEF was found to be an adjunct in heart failure (HF) trials, examining the usefulness of angiotensin-converting enzyme (ACE) inhibitors in